全文获取类型
收费全文 | 1808篇 |
免费 | 106篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 53篇 |
妇产科学 | 36篇 |
基础医学 | 244篇 |
口腔科学 | 31篇 |
临床医学 | 162篇 |
内科学 | 459篇 |
皮肤病学 | 23篇 |
神经病学 | 81篇 |
特种医学 | 36篇 |
外科学 | 207篇 |
综合类 | 36篇 |
预防医学 | 90篇 |
眼科学 | 107篇 |
药学 | 183篇 |
中国医学 | 6篇 |
肿瘤学 | 138篇 |
出版年
2023年 | 14篇 |
2022年 | 45篇 |
2021年 | 87篇 |
2020年 | 55篇 |
2019年 | 67篇 |
2018年 | 80篇 |
2017年 | 43篇 |
2016年 | 55篇 |
2015年 | 71篇 |
2014年 | 101篇 |
2013年 | 94篇 |
2012年 | 122篇 |
2011年 | 145篇 |
2010年 | 60篇 |
2009年 | 70篇 |
2008年 | 118篇 |
2007年 | 94篇 |
2006年 | 81篇 |
2005年 | 84篇 |
2004年 | 57篇 |
2003年 | 57篇 |
2002年 | 35篇 |
2001年 | 24篇 |
2000年 | 24篇 |
1999年 | 23篇 |
1998年 | 13篇 |
1997年 | 8篇 |
1996年 | 9篇 |
1995年 | 3篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 17篇 |
1991年 | 16篇 |
1990年 | 14篇 |
1989年 | 13篇 |
1988年 | 13篇 |
1987年 | 11篇 |
1986年 | 11篇 |
1985年 | 6篇 |
1984年 | 8篇 |
1983年 | 3篇 |
1981年 | 4篇 |
1979年 | 14篇 |
1978年 | 8篇 |
1977年 | 4篇 |
1973年 | 4篇 |
1971年 | 3篇 |
1970年 | 4篇 |
1967年 | 2篇 |
1965年 | 2篇 |
排序方式: 共有1919条查询结果,搜索用时 31 毫秒
91.
Gaurav Tyagi Utsav Gupta Ankit Verma Dhananjay Saxena Atul Mittal Amit Goyal Jeevan Kankaria R.K. Jenaw 《International journal of surgery case reports》2014,5(10):717-719
INTRODUCTION
Ileal pouch anal anastomosis (IPAA) after total proctocolectomy is a frequently performed surgery for medically refractory ulcerative colitis (UC). Volvulus of the ileal pouch as a complication of IPAA is extremely rare. We present a case of volvulus of S-type ileal pouch.PRESENTATION OF CASE
A 28 year old male, with history of total proctocolectomy with IPAA for severe UC in 2009 presented with signs of bowel obstruction. Emergency laparotomy was done and a volvulus of the S-type ileal pouch was derotated and pouchpexy done.DISCUSSION
The IPAA has a wide spectrum of complications, with obstruction of proximal small bowel occurring frequently. Volvulus of the ileal pouch is extremely rare with only 3 reported cases. Early diagnosis and intervention is important to salvage the pouch. Computed tomography (CT) may aid the diagnosis in stable patients.CONCLUSION
The diagnosis of ileal pouch volvulus although rare, should be kept in mind when dealing with patients complaining of recurrent obstruction following IPAA. 相似文献92.
Ravindra Tiwari Sunil Kumar Agarwal R. S. R. Murthy Shweta Tiwari 《Journal of pharmaceutical innovation》2014,9(3):246-258
The purpose of the present investigation is to emphasize the application of hot-melt extrusion technique (HMET) for the preparation of sustained release matrix formulation of highly dosed, freely soluble drugs. In this study, sustained release multiple unit dosage of venlafaxine hydrochloride (VH) was prepared by HMET. Custom design was used to screen the effect of four factors-type of polymer (ethylcellulose and eudragit RSPO) (X 1), amount of polymer (X 2), type of plasticizer (DBS, ATBC, TEC, and PEG) (X 3), and plasticizer concentration (X 4), on the drug release at 8 h (Y1) and machine torque (Y2). The experiments were carried out according to a four-factor 16-run statistical model and subjected to 12-h dissolution study in purified water. The significance of the model was indicated by ANOVA. Results of in vitro release study indicate that formulations prepared with higher amount of ethylcellulose and DBC show significant retardation at 8 h. The result shows that increase in concentration of polymer with the combination of water insoluble plasticizer (DBS and ATBC) has better sustained release while increasing concentration of TEC and PEG results faster in vitro release. Besides that increase in plasticizer concentration helps in reducing the melt temperature and machine torque. The in vivo study was performed, and formulations were compared using area under the plasma concentration-time curve (AUC0-∞), time to reach peak plasma concentration (Tmax), and peak plasma concentration (Cmax). The drug release profiles of extrudes were found to fit both diffusion and surface erosion models. Further to this, scanning electron microscopy, differential scanning calorimetry, and X-ray diffraction analysis of the hot-melt extrudates demonstrated that VH remained crystalline and was homogeneously dispersed throughout the polymer matrix. 相似文献
93.
Justin Taylor Mark T.A. Donoghue Caleb Ho Kseniya Petrova-Drus Hikmat A. Al-Ahmadie Samuel A. Funt Yanming Zhang Umut Aypar Pavitra Rao Shweta S. Chavan Michael Haddadin Roni Tamari Sergio Giralt Martin S. Tallman Raajit K. Rampal Priscilla Baez Rajya Kappagantula Satyajit Kosuri Ahmet Dogan Satish K. Tickoo Victor E. Reuter George J. Bosl Christine A. Iacobuzio-Donahue David B. Solit Barry S. Taylor Darren R. Feldman Omar Abdel-Wahab 《The Journal of clinical investigation》2020,130(12):6668
94.
Manish Kumar Jeengar Shweta Shrivastava Kala Nair Sreenivasa Reddy Singareddy Uday Kumar Putcha M. V. N. Kumar Talluri V. G. M. Naidu Ramakrishna Sistla 《Inflammation》2014,37(6):2139-2155
The purpose of the present study is to evaluate the effect of emu oil on bioavailability of curcumin when co-administered and to evaluate the property that enhances the anti-inflammatory potential of curcumin. Oral bioavailability of curcumin in combination with emu oil was determined by measuring the plasma concentration of curcumin by HPLC. The anti-inflammatory potential was evaluated in carrageenan-induced paw edema model (acute model) and in Freund’s complete adjuvant (FCA)-induced arthritis model (chronic model) in male SD rats. The anti-inflammatory potential of curcumin in combination with emu oil has been significantly increased in both acute and chronic inflammatory models as evident from inhibition of increase in paw volume, arthritic score, and expression of pro-inflammatory cytokines. The increased anti-inflammatory activity in combination therapy is due to enhanced bioavailability (5.2-fold compared to aqueous suspension) of curcumin by emu oil. Finally, it is concluded that the combination of emu oil with curcumin will be a promising approach for the treatment of arthritis. 相似文献
95.
96.
Jean Guillon Shweta Nim Stphane Moreau Luisa Ronga Solne Savrimoutou Elisabeth Thivet Mathieu Marchivie Attilio Di Pietro Rajendra Prasad Marc Le Borgne 《RSC advances》2020,10(5):2915
Two series of piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives were prepared via a Buchwald–Hartwig cross-coupling reaction and then evaluated for their ability to inhibit the drug efflux activity of CaCdr1p and CaMdr1p transporters of Candida albicans overexpressed in a Saccharomyces cerevisiae strain. In the initial screening of twenty-nine piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives, twenty-three compounds behaved as dual inhibitors of CaCdr1p and CaMdr1p. Only four compounds showed exclusive inhibition of CaCdr1p or CaMdr1p. Further biological investigations were developed and for example, their antifungal potential was evaluated by measuring the growth of control yeast cells (AD1-8u−) and efflux pump-overexpressing cells (AD-CDR1 and AD-MDR1) after exposition to variable concentrations of the tested compounds. The MIC80 values of nineteen compounds ranging from 100 to 901 μM for AD-CDR1 demonstrated that relative resistance index (RI) values were between 8 and 274. In comparison, only seven compounds had RI values superior to 4 in cells overexpressing Mdr1p. These results indicated substrate behavior for nineteen compounds for CaCdr1p and seven compounds for CaMdr1p, as these compounds were transported via MDR transporter overexpressing cells and not by the AD1-8u− cells. Finally, in a combination assay with fluconazole, two compounds (1d and 1f) have shown a synergistic effect (fractional inhibitory concentration index (FICI) values ≤ 0.5) at micromolar concentrations in the AD-MDR1 yeast strain overexpressing CaMdr1p-protein, indicating an excellent potency toward chemosensitization.Two series of piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives were prepared via a Buchwald–Hartwig cross-coupling reaction and then evaluated for their ability to inhibit the drug efflux activity of two Candida albicans transporters. 相似文献
97.
Sameera Nayak Taraprasad Das Deepika Parameswarappa Savitri Sharma Saumya Jakati Subhadra Jalali Raja Narayanan Soumyava Basu Mudit Tyagi Vivek Pravin Dave Rajeev Reddy Pappuru Avinash Pathengay Hrishikesh Kaza Padmaja Kumari Rani Shashwat Behera Niroj Kumar Sahoo Aditya Kapoor Hitesh Agrawal Komal Agarwal Brijesh Takkar Vishal Ramesh Raval 《Indian journal of ophthalmology》2021,69(12):3664
Purpose:Intraocular infection in patients with COVID-19 could be different in the presence of treatment with systemic corticosteroid and immunosuppressive agents. We describe the epidemiology and microbiological profile of intraocular infection in COVID-19 patients after their release from the hospital.Methods:We analyzed the clinical and microbiological data of laboratory-confirmed COVID-19 patients from April 2020 to January 2021 presenting with features of endogenous endophthalmitis within 12 weeks of their discharge from the hospital in two neighboring states in South India. The data included demography, systemic comorbidities, COVID-19 treatment details, time interval to visual symptoms, the microbiology of systemic and ocular findings, ophthalmic management, and outcomes.Results:The mean age of 24 patients (33 eyes) was 53.6 ± 13.5 (range: 5–72) years; 17 (70.83%) patients were male. Twenty-two (91.6%) patients had systemic comorbidities, and the median period of hospitalization for COVID-19 treatment was 14.5 ± 0.7 (range: 7–63) days. Infection was bilateral in nine patients. COVID-19 treatment included broad-spectrum systemic antibiotics (all), antiviral drugs (22, 91.66% of patients), systemic corticosteroid (21, 87.5% of patients), supplemental oxygen (18, 75% of patients), low molecular weight heparin (17, 70.8% of patients), admission in intensive care units (16, 66.6% of patients), and interleukin-6 inhibitor (tocilizumab) (14, 58.3% of patients). Five (20.8%) patients died of COVID-19-related complications during treatment for endophthalmitis; one eye progressed to pan ophthalmitis and orbital cellulitis; eight eyes regained vision >20/400. Fourteen of 19 (73.7%) vitreous biopsies were microbiologically positive (culture, PCR, and microscopy), and the majority (11 patients, 78.5%) were fungi.Conclusion:Intraocular infection in COVID-19 patients is predominantly caused by fungi. We suggest a routine eye examination be included as a standard of care of COVID-19. 相似文献
98.
Sachin Kochrekar Ajit Kalekar Shweta Mehta Pia Damlin Mikko Salomki Sari Granroth Niko Meltola Kavita Joshi Carita Kvarnstrm 《RSC advances》2021,11(32):19844
This study reports the electropolymerization of novel keto functionalized octaethyl metal porphyrins (Zn2+ and Ni2+) in the presence of 4,4′-bipyridine (4,4′-bpy) as a bridging nucleophile. The polymer films were characterized by electrochemical, spectroscopic (UV-Vis, XPS, FT-IR and Raman spectroscopy) and imaging (AFM and SEM) techniques. The absorption and electronic spectra confirm the presence of both porphyrin and 4,4′-bipyridine units in the film. The surface morphology reveals homogeneous film deposition with average roughness values of approx. 8 nm. The theoretical studies performed offered insights into the interplay of different metal centres (Zn2+ and Ni2+) and the keto functionality of the porphyrin unit in the formation of copolymer films. The electrochemical interaction of polymer films with CO2 suggests a reversible trap and release of CO2 with low energy barriers for both the polymers.Electropolymerization of keto functionalized porphyrins and 4,4′-bipyridine. 相似文献
99.
C R Vishwaraj Srinivasan Kavitha Rengaraj Venkatesh Aakriti Garg Shukla Premanand Chandran Shweta Tripathi 《Indian journal of ophthalmology》2022,70(2):380
Neuroprotective therapies in glaucoma may play a role in preventing ischemia and oxidative damage that results in apoptosis of retinal ganglion cells and optic nerve damage. Although intraocular pressure (IOP) is the only known modifiable risk factor for glaucoma, disease progression commonly occurs despite IOP control, suggesting that factors other than IOP play a role in its pathogenesis and can potentially act as targets for neuroprotection. Factors including mediators of apoptosis, ischemic changes, poor ocular blood flow and neurotoxins have been hypothesized to play a role in glaucoma progression. Neuroprotective targets include glutamate-induced neurotoxicity, nitric oxidase synthetase, neurotropins, calcium channel receptors, free radicals, vascular insufficiency, the rho-kinase pathway, and more. Drugs related to these factors are being evaluated for their role in neuroprotection, although this area of investigation faces several challenges including limited evidence for these agents’ efficacy in clinical studies. Additionally, while IOP-lowering therapies are considered neuroprotective as they generally slow the progress of glaucoma progression, they are limited by the extent of their effect beyond IOP control. The aim of this article is to review the current treatment options available for neuroprotection and to explore the drugs in the pipeline. 相似文献
100.